Enzalutamide with radiation for recurrent prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a drug called enzalutamide to standard radiation and metastasis-directed therapy improves outcomes for men with recurrent prostate cancer that has spread to a few spots. It's for those whose PSA is rising quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with prostate cancer (adenocarcinoma).
- Your PSA level must be rising after initial treatment.
- Your PSA doubling time must be 9 months or less.
- You must have 1 to 5 distant metastases on PSMA PET/CT scan.
- You must be 18 years or older and in good general health (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug rezvilutamide to standard hormone therapy, along with prostate removal surgery and precise radiation to cancer spots, helps men whose prostate cancer has spread to a limited number of places (no more than 10 spots, and not in organs like the liver or lungs).
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.